The healthcare provider has ordered 1000 mL of 0.9% sodium chloride to be administered intravenously over 5 hours. The drop factor on the tubing is 15 drops/mL. How many milliliters per hour will you administer and how many drops per minute?

A) Treatment with PPIs to decrease stomach acid:
Pancreatic insufficiency is not primarily related to excess stomach acid production, so treatment with proton pump inhibitors (PPIs) to decrease stomach acid would not address the underlying cause of the condition.

B) Treatment with stimulant laxatives:
Pancreatic insufficiency is not typically associated with constipation or the need for stimulant laxatives. While malabsorption of fats due to pancreatic insufficiency can lead to loose stools or diarrhea, treatment with laxatives is not indicated for this condition.

C) Replacement therapy with pancreatic enzymes.
Pancreatic insufficiency occurs when the pancreas does not produce enough digestive enzymes to properly digest food, leading to malabsorption of nutrients. Replacement therapy with pancreatic enzymes is the mainstay of treatment for pancreatic insufficiency. These pancreatic enzyme supplements help to replace the deficient enzymes, aiding in the digestion and absorption of nutrients from food. By taking pancreatic enzyme supplements with meals, the client can improve digestion and prevent nutritional deficiencies associated with pancreatic insufficiency.

D) Decrease food intake:
Decreasing food intake would not address the underlying cause of pancreatic insufficiency, which is the deficiency of pancreatic enzymes needed for proper digestion. In fact, decreasing food intake could exacerbate malnutrition and nutrient deficiencies in individuals with pancreatic insufficiency. The primary goal of treatment is to improve digestion and nutrient absorption by providing supplemental pancreatic enzymes with meals.

A) Theophylline:
Theophylline is a bronchodilator medication that is used for the long-term management of asthma and chronic obstructive pulmonary disease (COPD). It has a slower onset of action compared to short-acting beta-agonists like albuterol and is not typically used as the initial treatment for acute asthma exacerbations.

B) Montelukast:
Montelukast is a leukotriene receptor antagonist used for the long-term control and prevention of asthma symptoms, but it is not typically used as the initial treatment for acute asthma exacerbations. Its onset of action is slower compared to short-acting beta-agonists like albuterol.

C) Albuterol.
Albuterol is a short-acting beta agonist bronchodilator commonly used as a first-line treatment for acute asthma exacerbations. It works by quickly relaxing the smooth muscles of the airways, leading to rapid bronchodilation and improvement of airflow. This can help alleviate the patient's symptoms of shortness of breath and wheezing.

D) Salmeterol:
Salmeterol is a long-acting beta-agonist bronchodilator used for the maintenance treatment of asthma and COPD, but it is not typically used as the initial treatment for acute asthma exacerbations. Its onset of action is slower compared to short-acting beta-agonists like albuterol, and it is not recommended for rapid relief of acute symptoms.